Endothelial cell infection and endotheliitis in COVID-19
- Z. Varga, A. Flammer, H. Moch
- MedicineThe Lancet
- 20 April 2020
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
- C. Barbieri, S. Baca, L. Garraway
- Biology, MedicineNature Genetics
- 1 May 2012
SPOP mutations may define a new molecular subtype of prostate cancer, with mutations involving the SPOP substrate-binding cleft in 6–15% of tumors across multiple independent cohorts.
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
- M. Peifer, L. Fernandez-Cuesta, Roman K. Thomas
- BiologyNature Genetics
- 1 October 2012
This study implicates histone modification as a major feature of SCLC, reveals potentially therapeutically tractable genomic alterations and provides a generalizable framework for the identification of biologically relevant genes in the context of high mutational background.
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours.
- H. Moch, A. Cubilla, P. Humphrey, V. Reuter, T. Ulbright
- MedicineEuropean Urology
- 1 July 2016
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia
- J. Srigley, B. Delahunt, P. Argani
- MedicineAmerican Journal of Surgical Pathology
- 1 October 2013
The classification working group of the International Society of Urological Pathology consensus conference on renal neoplasia was in charge of making recommendations regarding additions and changes to the current World Health Organization Classification of Renal Tumors, with consensus that 5 entities should be recognized as new distinct epithelial tumors within the classification system.
Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
- J. Weiss, M. Sos, Roman K. Thomas
- Medicine, BiologyScience Translational Medicine
- 15 December 2010
F focal FGFR1 amplification is common in squamous cell lung cancer and associated with tumor growth and survival, suggesting that FGFR inhibitors may be a viable therapeutic option in this cohort of patients.
High-throughput oncogene mutation profiling in human cancer
- Roman K. Thomas, Alissa C. Baker, L. Garraway
- BiologyNature Genetics
- 1 March 2007
High-throughput genotyping is adapted to query 238 known oncogene mutations across 1,000 human tumor samples and established robust mutation distributions spanning 17 cancer types, offering a new dimension in tumor genetics, where mutations involving multiple cancer genes may be interrogated simultaneously and in 'real time'.
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
- L. Schmidt, F. Duh, B. Zbar
- Biology, MedicineNature Genetics
- 1 May 1997
Spectrum of Epithelial Neoplasms in End-Stage Renal Disease: An Experience From 66 Tumor-Bearing Kidneys With Emphasis on Histologic Patterns Distinct From Those in Sporadic Adult Renal Neoplasia
- S. Tickoo, M. Deperalta-Venturina, M. Amin
- MedicineAmerican Journal of Surgical Pathology
- 1 February 2006
A broad spectrum of renal cell tumors exist in ESRD, only some of which resemble the sporadic RCCs, and only the acquired cystic disease-associated RCC appears to be more aggressive than the other tumor subtypes in E SRD.
Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients.
- L. Bubendorf, A. Schöpfer, M. Mihatsch
- MedicineHuman Pathology
- 1 May 2000
It is shown that bone, lung, and liver are the most frequent sites of distant prostate cancer metastases and there are strong arguments for the existence and clinical significance of a backward venous spread to the spine, which is likely to occur early in the metastatic process.
...
...